ResMed Inc (RMD)vsStereotaxis Inc (STXS)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
STXS
Stereotaxis Inc
$1.88
+4.17%
HEALTHCARE · Cap: $174.08M
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 16573% more annual revenue ($5.40B vs $32.38M). RMD leads profitability with a 27.5% profit margin vs -66.8%. STXS appears more attractively valued with a PEG of 1.31. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
STXS
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Intrinsic value data unavailable for STXS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Revenue surging 36.3% year-over-year
Areas to Watch
No major concerns identified
Trading at 13.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : STXS
The strongest argument for STXS centers on Revenue Growth. Revenue growth of 36.3% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : STXS
The primary concerns for STXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
RMD profiles as a mature stock while STXS is a hypergrowth play — different risk/reward profiles.
STXS carries more volatility with a beta of 1.40 — expect wider price swings.
STXS is growing revenue faster at 36.3% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 34/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Stereotaxis Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?